Tigecycline: A new antibiotic

References 

1. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double blind phase 3 comparison study with vancomycin and aztreonam. Antimicrobial Agents and Chemotherapy. 2005;49:4658–4666
2. Formin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. International Journal of Surgery. 2005;3:35–47
3. Olivia ME, Rekha A, Yellin A. et al. A muticentre trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections. BMC Infectious Diseases 2005; 5:88. Available at www.biomedcentral.com/1471-2334-5-88.
4. Sacchidanand S, Penn RL, Embil JM, et al. Effiacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam on patients with complicated skin and skin structure infections: results from a phase 3, randomised, double blind trial. International Journal of Infectious diseases. 2005;9:251–261
5. Sader H, Jones R, Dowzicky M, et al. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalised in the intensive care unit. Diagnostic Microbiology and Infectious Disease. 2005;52:203–208
   • Abstract
   • Full Text
   • Full-Text PDF (116 KB)
   • CrossRef
6. Summary of Product Characteristics-Tygacil™. Wyeth Pharmaceuticals. May, 2006.